Collaboration Agreements, Licenses and Other Research and Development Agreements (Details Narrative) - USD ($) |
3 Months Ended | |||||
|---|---|---|---|---|---|---|
Nov. 19, 2021 |
Nov. 19, 2020 |
Dec. 12, 2019 |
Mar. 31, 2022 |
Mar. 31, 2021 |
Dec. 31, 2021 |
|
| Revenue | $ 33,333 | |||||
| Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | ||||||
| Therapeutics development award | $ 4,200,000 | |||||
| Proceeds from award | $ 484,000 | |||||
| Additional milestone payment | $ 321,000 | |||||
| CFF Agreement [Member] | ||||||
| Grants Receivable | 3,600,000 | |||||
| Additional milestone payment | 4,500,000 | |||||
| CFF Agreement [Member] | Accrued Expense and Other Current Liabilities [Member] | ||||||
| Other Liabilities | $ 669,000 | $ 899,000 | ||||
| Genentech Feasibility Study Agreement [Member] | Genentech [Member] | ||||||
| Agreement description | Under the terms of the Genentech Agreement, Genentech paid the Company a total of $100 thousand for the development of three molecules, or approximately $33 thousand per molecule, which is being recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement. | |||||
| Deferred revenue | $ 100,000 | |||||
| Revenue | $ 33,000 | |||||
| X | ||||||||||
- Definition Additional milestone payment. No definition available.
|
| X | ||||||||||
- Definition Agreement description. No definition available.
|
| X | ||||||||||
- Definition Commitment payment. No definition available.
|
| X | ||||||||||
- Definition Proceeds from award. No definition available.
|
| X | ||||||||||
- Definition Therapeutics development award. No definition available.
|
| X | ||||||||||
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|